Every 8-K that AETHLON MEDICAL INC (AEMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AEMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AEMD filings page.
AETHLON MEDICAL INC (AEMD) reported an update on its capital structure. Following recent exercises of certain pre-funded warrants, the company has 1,604,095 shares of common stock outstanding as of the close of business on August 28, 2026. The company states that, as a result of these exercises, all previously outstanding pre-funded warrants have been exercised, leaving no such warrants remaining outstanding.
Aethlon Medical, Inc. reported fiscal first-quarter 2027 results for the quarter ended June 30, 2026 and provided an update on its Hemopurifier program. Clinically, the company dosed the first participant in the third and final cohort of its Phase 1 oncology study in Australia. Early observations from the first two cohorts showed consistent decreases in tumor-derived extracellular vesicles and cancer‑linked microRNAs and signs of immune changes; these findings are preliminary and will be fully evaluated after study completion. A Long COVID manuscript describing extracellular vesicles in patients was accepted for publication, showing that these vesicles bind to the Hemopurifier’s GNA affinity resin.
Cash and cash equivalents were approximately $4.9 million as of June 30, 2026. Subsequent to quarter‑end, the company raised about $4.0 million in gross proceeds via a public offering and believes its cash resources can fund operations for at least the next 12 months. Consolidated operating expenses decreased 11.9% to about $1.6 million from $1.8 million in the prior‑year quarter, and operating loss narrowed accordingly. Net loss attributable to common stockholders was $1.55 million, or $4.02 per share, compared with $1.76 million, or $42.42 per share, a year earlier.
Aethlon Medical, Inc. approved a 1-for-5 reverse stock split of its issued and outstanding common stock through a Certificate of Change filed under Nevada law. The company cites this move as part of its capital-markets and operating plan, including dilution management and continued compliance with Nasdaq Listing Rule 5550(a)(2).
The reverse split will be effective at 10:00 a.m. Eastern Time on July 31, 2026, with AEMD shares expected to begin trading on a split-adjusted basis on August 4, 2026 under the same symbol and a new CUSIP of 00808Y703. Every five pre-split shares will be combined into one share, with no cash paid for fractional shares; instead, any fractional entitlement will be rounded up to one whole post-split share.
Authorized common stock will decrease from 100,000,000 to 20,000,000 shares. Based on 3,249,569 shares outstanding as of July 23, 2026, there will be approximately 649,914 shares outstanding after the split, subject to rounding. The company states that each holder’s percentage ownership and voting power will remain virtually unchanged, preferred stock authorization is unaffected, and outstanding options, warrants and convertible securities will be adjusted proportionately. Under Nevada statutes, the board approved the transaction without a stockholder vote.
Aethlon Medical, Inc. entered into a securities purchase agreement and priced a follow-on offering of approximately $4.0 million, selling 5,633,009 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 5,633,009 shares at $0.7101 per share (or pre-funded warrant) and accompanying warrant. The offering, priced at-the-market under Nasdaq rules, is expected to close on or about July 7, 2026, with Maxim Group LLC as sole placement agent. Aethlon expects net proceeds of about $3.335 million after fees and expenses, which it plans to use mainly for general corporate purposes including research and development, clinical trials, capital expenditures, and working capital. Company officers and directors agreed to 90-day lock-ups, and Aethlon accepted restrictions on additional equity issuances for up to one year, subject to specified exceptions.
Aethlon Medical, Inc. reported fiscal year 2026 results showing a substantially narrower loss while advancing its Hemopurifier program. Net loss attributable to common stockholders was $7.2 million for the year ended March 31, 2026, compared with $13.4 million a year earlier as operating expenses fell 21.9% to about $7.3 million.
Other income was $142,000 versus other expense of $4.0 million in the prior year, which had included significant non-cash financing charges. Cash and cash equivalents were about $5.0 million at March 31, 2026, and the company subsequently raised roughly $1.85 million in net proceeds through its at-the-market program.
Clinically, Aethlon advanced its Australian oncology trial into the third and final dosing cohort after independent safety review, treated the first Cohort 3 participant, and continued preclinical work in rheumatoid arthritis and chronic kidney disease. It also obtained new U.S. and European patents for Hemopurifier applications in COVID-19 and Long COVID, extending certain protections into the 2040s.
Aethlon Medical, Inc. updated its at-the-market equity program, allowing sales of common stock with an aggregate offering price of up to $542,716 under its existing agreement with H.C. Wainwright & Co. pursuant to an amended prospectus supplement.
This new capacity follows prior sales of common stock totaling $1,849,457 under the same prospectus. As of June 1, 2026, Aethlon had 2,344,886 shares of common stock outstanding, including 2,337,629 shares held by non-affiliates used to calculate its public float under Form S-3 rules.
Aethlon Medical, Inc. reported that, following recent exercises of certain pre-funded warrants, it has 1,569,110 shares of common stock outstanding as of the close of business on March 16, 2026. The company stated that all previously outstanding pre-funded warrants have now been exercised, simplifying its capital structure by converting those warrant rights into common shares.
Aethlon Medical, Inc. held its Annual Meeting on February 19, 2026, where stockholders approved several measures that significantly expand the company’s equity capacity. The Articles of Incorporation were amended to increase authorized common stock from 6,000,000 to 100,000,000 shares.
Stockholders also approved adding 100,000 shares to the 2020 Equity Incentive Plan and ratified Haskell & White LLP as auditor for the year ending March 31, 2026. For Nasdaq Listing Rule 5635(d) purposes, stockholders approved the potential issuance of up to 1,662,553 shares of common stock tied to various warrants under a Securities Purchase Agreement dated December 5, 2025, and up to 368,471 shares issuable upon exercise of additional warrants from a Warrant Inducement Agreement. The meeting had a quorum, with 556,359 of 973,213 outstanding shares represented.
Aethlon Medical reported fiscal Q3 2026 results showing continued operating losses but significant cost discipline. For the quarter ended December 31, 2025, operating expenses were about $2.06 million, up from $1.81 million a year earlier, leading to an operating loss of $2.06 million and a net loss of $2.02 million.
Over the nine months ended December 31, 2025, operating expenses fell 26.9% to about $5.36 million from $7.34 million, driven by lower payroll, general and administrative, and professional fees. Cash and cash equivalents were about $7.0 million as of December 31, 2025, with total assets of $8.06 million.
The company highlighted continued compliance with Nasdaq listing requirements, progress in its Australian oncology trial Cohort 2, advancement of its Long COVID and extracellular vesicle research, and ongoing evaluation of Hemopurifier compatibility with simplified blood treatment systems. Management noted that cash on hand may not be sufficient to support operations for the next 12 months without additional financing.
Aethlon Medical, Inc. entered into two amendments on January 22, 2026 that change the terms of an existing financing arrangement with an institutional investor. The company amended its Securities Purchase Agreement and a related Pre-Funded Common Stock Purchase Warrant so that it no longer needs to obtain shareholder approval under Nasdaq Rule 5635 before the pre-funded warrants can be issued or exercised.
As a result of these amendments, the pre-funded warrants held by the investor are now immediately exercisable. All other terms of the original Securities Purchase Agreement remain in place. The full legal details of the changes are provided in the amendments filed as exhibits to the report.
Aethlon Medical, Inc. entered into a private PIPE financing and a related warrant inducement to raise approximately $3.3M in gross proceeds. In the PIPE, the company agreed to sell 596,452 shares of common stock (or pre-funded warrants in lieu of shares) and issue 1,043,791 Common Warrants, each unit priced at $4.03. The Common Warrants carry a $4.03 exercise price, become exercisable after stockholder approval of the underlying shares, and expire 5.5 years after that approval.
Separately, Aethlon signed a warrant inducement agreement under which a holder of existing warrants may exercise those warrants for cash at a reduced exercise price of $4.03 per share and receive new warrants equal to 175% of the exercised warrant shares, also at a $4.03 exercise price and a 5.5‑year term after stockholder approval. The company plans to use net proceeds for working capital and general corporate purposes and agreed to file resale registration statements for both the PIPE securities and the new warrants, with liquidated damages if certain registration deadlines are missed.
Aethlon Medical, Inc. furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference into Item 2.02.
The company states the information under Item 7.01 (Regulation FD), including Exhibit 99.1, is being furnished and not deemed filed under the Exchange Act, and will not be incorporated into other filings except by specific reference.
Aethlon Medical (AEMD) announced it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Capital Market. Nasdaq confirmed on November 5 that the matter is closed.
The company had received a notice on October 16 that its common stock had closed below the $1.00 minimum for 30 consecutive business days. Regaining compliance required maintaining a closing bid of at least $1.00 per share for ten consecutive business days, which the company achieved.
This update removes the immediate listing deficiency and keeps AEMD’s shares trading on Nasdaq, preserving market visibility and liquidity associated with that venue.
Aethlon Medical reported it is not in compliance with Nasdaq’s minimum bid price rule after its common stock closed below $1.00 for 30 consecutive business days. The company received the notice on October 16, 2025 and has requested a hearing before a Nasdaq Hearings Panel, which stays any suspension or delisting action while the panel reviews the case. The stock will continue trading on the Nasdaq Capital Market under the symbol AEMD during this process.
As part of its plan to regain compliance, Aethlon implemented a 1‑for‑10 reverse stock split effective October 16, 2025, with split-adjusted trading beginning on October 20, 2025. The company is monitoring its closing bid price and may evaluate additional actions to maintain its listing on the Nasdaq Capital Market.
Aethlon Medical (AEMD) implemented a 1-for-10 reverse stock split, effective at 10:00 a.m. Eastern on October 16, 2025. The stock is expected to begin trading on a split-adjusted basis on October 20, 2025 under the AEMD symbol, with a new CUSIP of 00808Y604.
The move is part of the company’s capital‑markets plan, including continued compliance with Nasdaq Listing Rule 5550(a)(2). Authorized common shares will change from 60,000,000 to 6,000,000. Common shares outstanding were 7,612,106 as of October 16, 2025, which will become approximately 761,210 after the split, subject to rounding. No fractional shares will be issued; holders otherwise entitled to a fraction will receive one whole share. Options, warrants and other convertibles will be adjusted proportionally.
No stockholder approval was required under Nevada law (NRS 78.207/78.209). Computershare is the transfer and exchange agent. Percentage ownership and voting power remain substantially unchanged aside from rounding.
Aethlon Medical, Inc. (AEMD) filed a Form 8-K reporting a material event dated September 4, 2025 that primarily attaches transaction documents and a press release. The filing includes forms of a Common Warrant, Pre-Funded Warrant, and a Placement Agent Warrant, a Warrant Agency Agreement with Computershare, a Securities Purchase Agreement with investors, a Placement Agency Agreement with Maxim Group, LLC, and a Press Release dated the same day.
The exhibits indicate the company executed a financing-related transaction structure involving warrants and a placement agent; the warrant agency relationship was documented with Computershare. The filing text is an exhibits list and does not disclose pricing, proceeds, or specific investor identities within the provided content.
Aethlon Medical, Inc. furnished an updated corporate investor presentation that may be used in conferences and investor meetings. The presentation, dated August 20, 2025, is available on the company’s website and is attached as Exhibit 99.1. The company emphasizes that this material is being provided under Regulation FD as “furnished, not filed,” meaning it is not subject to certain liability provisions of the securities laws and is not automatically incorporated into other SEC filings unless specifically referenced. This update is primarily an informational disclosure for investors and other stakeholders, rather than a report of new financial results or a major transaction.
Aethlon Medical (Nasdaq:AEMD) filed a Form 8-K to furnish its press release announcing financial results for the quarter ended March 31, 2025. Reported under Items 2.02 and 7.01, the filing attaches the release as Exhibit 99.1 and states the information is provided under Regulation FD and not deemed “filed” for Exchange Act purposes. No detailed financial metrics, guidance, or strategic updates are included in the 8-K itself. Aside from furnishing the exhibit, the report discloses no material events likely to affect the company’s operating outlook or capital structure. Investors must review Exhibit 99.1 for the actual results.